Abstract 4541
Background
Patients (pts) with advanced cancer have high rates of healthcare resource utilization at the end of life (EOL). Immunotherapy (IO) has changed the treatment landscape for many patients with cancer. The impact of IO on resource utilization at the EOL for pts with metastatic disease, including emergency department (ED) visits, hospitalizations, and referrals to hospice is unknown.
Methods
We conducted a single center, retrospective analysis of pts treated with PD-1/L1 or CTLA-4 antibodies alone or in combination from 2011 – 2017. We identified 1,113 pts from electronic health records and present here clinical information for 306 pts with metastatic disease and end of life outcome data for 188 decedents. Survival curves were compared using log-rank test for pts by disease, treatment type, ECOG performance status (PS) at treatment start, and age. Hospice referral rate was compared using Fisher’s exact test.
Results
Of the 306 pts, 131 (43%) had melanoma, 42 (14%) had renal cell carcinoma, 33 (11%) had non-small cell lung cancer, 22 (7%) had head and neck carcinoma, and 78 (25%) had another advanced malignancy. Treatment consisted of nivolumab in 130 (42%) pts, ipilimumab in 73 (24%), pembrolizumab in 59 (19%), nivolumab/ipilimumab in 23 (8%), atezolizumab in 9 (3%), and other IO combinations in 12 (4%). Of the 188 (61%) pts who died, 93 (49%) had at least one ED visit in the last month of life, 110 (59%) had at least one hospitalization, and 21 (11%) died in the hospital. Of all pts who died, 156 (83%) had hospice referral with a median of 11 days (range 1-420) between hospice referral and death. Overall survival (OS) was not associated with disease type (p = 0.11) or treatment (p = 0.832), but was associated with ECOG PS (p = 0.013). Referral to hospice did not vary by disease type (p = 0.945), treatment type, (p = 0.809) or age (p = 0.432), but did vary by ECOG PS (p = 0.006). Death within 72 hours of hospice referral rate varied significantly by inpatient or outpatient referral (p = 0.002).
Conclusions
Hospitalizations and ED visits are frequent at the EOL among pts who received IO for advanced malignancies. There was a high referral rate to hospice, but the median time between hospice referral and death was short. Interventions to decrease aggressive EOL care are needed.
Clinical trial identification
Legal entity responsible for the study
Jarred Burkart.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
A.M. Noonan: Paid member of a data safety monitoring board from 2016-2017: Helsinn. All other authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract